Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
3.700
+0.155 (4.37%)
Apr 27, 2026, 4:00 PM EDT - Market closed
Turn Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
A novel polymer-based ointment with a unique IL-36/IL-31 inhibition mechanism is advancing through a phase II eczema trial, with interim and top-line data expected in Q2 2026. The company is also pursuing onychomycosis and other dermatology indications, supported by strong IP and a low burn rate.
-
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.